Articles from Precigen, Inc
Precigen Posts Strong Q3: PAPZIMEOS Net Revenue Rose 37%; Positive Cash Flow Achieved Ahead of Schedule
Widespread adoption underwayFive-year data suggest lasting disease control and prolonged freedom from surgeryNew competing product said to face substantial uncertaintyBiotech in the News: The Longview
By Precigen, Inc · Via ACCESS Newswire · November 10, 2026